Clinical trials: Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
- Trial name
- NCT01023516
- Testing
- AZD9668
- Where
- 66 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Asthma, Obesity
Oxidative Stress in Asthma
40% of all asthma patients in the US are obese. Obese asthmatics have more severe disease than lean asthmatics and do not respond as well to conventional anti-inflammatory therapies.
- Trial name
- NCT04512547
- Testing
- Hyperpolarized 129XeMRI
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Asthma
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
- Trial name
- NCT02219048
- Testing
- PF-03715455
- Where
- 28 sites in United States
- Volunteers
- 51 people
- Sponsor
- Pfizer
Asthma
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic…
- Trial name
- NCT00995904
- Testing
- 84ug MAP0020, 42ug MAP0020, 21ug MAP0020
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD
- Trial name
- NCT02603393
- Testing
- QVA149, Tiotropium, Salmeterol/fluticasone
- Where
- 167 sites in Argentina, Austria and 19 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Asthma
The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma
The study evaluates the safety and efficacy of intralymphatic allergen-specific immunotherapy given to adolescents and young adults who are allergic to grass or birch pollen and have mild or moderate asthma.
- Conditions
- Rhinitis, Asthma, Allergy
- Trial name
- NCT03394508
- Testing
- ALK Alutard birch or 5-grasses, ALK diluent 0,3% human albumin
- Volunteers
- 30 people
- Sponsor
- Karolinska Institutet
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary…
- Trial name
- BEACON (NCT01529632)
- Testing
- QVA149, NVA237, QAB149
- Where
- 26 sites in Austria, Denmark and 3 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
COPD, Emphysema
Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations
The researchers are trying to explore the benefit of Health Coaching on patients with severe symptoms of COPD.
- Trial name
- NCT03837847
- Testing
- Health Coaching Calls, Control
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Asthma
Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing
The purpose of this study is to determine whether OM-85 BV (Broncho-Vaxom)has any effect on respiratory infections, infection related wheezing attacks, beta-2 agonist use, duration of attacks and effect on serum cytokine levels.
- Trial name
- NCT00733226
- Testing
- OM-85 BV (Broncho-Vaxom)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Kecioren Education and Training Hospital
Alpha-1 Antitrypsin Deficiency, Emphysema
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
The aim of this study is to test whether aspirin improves endothelial function in alpha-1 antitrypsin deficiency-associated lung disease, measured by pulmonary microvascular blood flow on magnetic resonance imaging (MRI) and with…
- Conditions
- Alpha-1 Antitrypsin Deficiency, Emphysema, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03008915
- Testing
- Aspirin, Withdrawal from alpha1 antitrypsin replacement therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Chronic Obstructive Pulmonary Disease
The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine whether exercise can be prolonged in COPD can by the inhaled bronchodilator Stiolto Respimat.
- Trial name
- NCT02845752
- Testing
- Stiolto Respimat
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Pulmonary Disease, Chronic Obstructive
Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by inflammation-mediated damage to lung tissue.
- Trial name
- NCT01387178
- Testing
- fluticasone propionate/salmeterol 250µg/50µg (FSC), tiotropium bromide (TIO)
- Volunteers
- 22,223 people
- Sponsor
- GlaxoSmithKline
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
- Trial name
- NCT01172808
- Testing
- tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Where
- 114 sites in United States, Brazil and 9 more
- Volunteers
- 1,071 people
- Sponsor
- Boehringer Ingelheim
COPD, Cystic Fibrosis
Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders
The purpose of this study is to test the efficacy of Hyperpolarized Helium-3 gas in MR imaging in COPD, asthmatics, CF and healthy volunteers.
- Conditions
- COPD, Cystic Fibrosis, Asthma, Healthy
- Trial name
- NCT00846573
- Testing
- Hyperpolarized Helium-3
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Asthma
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma
This research aims to find out how the inflammation in patients suffering from severe asthma is different from that in non-severe asthma, and how it may prevent corticosteroids from working efficiently in severe asthma.
- Trial name
- NCT00676572
- Testing
- Fiberoptic bronchoscopy; blood test
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Imperial College London
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers
The primary objective of this study is to evaluate the efficacy and safety of orally inhaled tiotropium and olodaterol as both a fixed dose combination and a free combination with respect to lung function and ECG parameters
- Trial name
- NCT02030535
- Testing
- olodaterol, tiotropium
- Where
- 6 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Asthma
Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances.
- Trial name
- NCT00200850
- Testing
- House Dust Mite SLIT, High dose SLIT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Chronic Obstructive Pulmonary Disease
A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose
This is a Phase I open-label, single center study to assess the PK and safety of BGF MDI 320/14.4/9.6 µg in subjects with moderate to severe COPD.
- Trial name
- NCT03250182
- Testing
- PT010
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.